新闻中心
关注我们
17 Dec
2018

知临集团宣布完成首次公开募股

<BUSINESS WIRE>
(新闻只有英文版本)

Aptorum Group Limited (“Aptorum”, or the “Company”), a Hong Kong based pharmaceutical company currently in the preclinical stage, dedicated to developing and commercializing therapeutic projects and diagnostic technologies to tackle unmet medical needs, today announced the closing of its initial public offering (“IPO” or the “Offering”) of 761,419 Class A Ordinary Shares, at a public offering price of $15.80 per share. The aggregate gross proceeds to Aptorum from the offering were $12,030,420, before deducting underwriting discounts and commissions and other offering expenses. While certain selling shareholders are offering to resell up to 1,595,235 Class A Ordinary Shares subject to certain lock-up periods, as applicable, none of the gross proceeds of the IPO will be used to purchase the selling shareholders’ securities nor will the Company receive any proceeds from the selling shareholders’ resale. The shares are expected to commence trading on The NASDAQ Global Market on December 18, 2018 at any time between 11:00 a.m. to 12:00 p.m. ET, under the ticker symbol “APM.”

Boustead Securities, LLC, China Renaissance Securities (HK) Limited, and AMTD Global Markets Limited acted as co-underwriters for the offering.

A registration statement has been filed with the SEC and became effective on December 3, 2018. This offering was made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained from Boustead Securities, LLC, email: offerings@boustead1828.com or by calling +1 (949) 502-4409 or standard mail at Boustead Securities, LLC, Attn: Equity Capital Markets, 6 Venture, Suite 265, Irvine, CA 92618, USA.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the Company's securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any sale of such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Aptorum Group Limited

We are a Hong Kong based pharmaceutical company currently in the preclinical stage, dedicated to developing and commercializing a broad range of therapeutic and diagnostic technologies to tackle unmet medical needs. We have obtained exclusive licenses for our technologies. In addition, we are also developing certain proprietary technologies as product candidates. We are pursuing therapeutic and diagnostic projects (including projects seeking to use extracts or derivatives from natural substances to treat diseases) in neurology, infectious diseases, gastroenterology, oncology and other disease areas. We also have projects focused on surgical robotics. In addition, we opened a medical clinic, AML Clinic, in June 2018. Its initial focus is on treatment of chronic diseases resulting from modern sedentary lifestyles and aging population. For more information about the Company, please visit www.aptorumgroup.com.

About Boustead Securities, LLC

Boustead Securities, LLC ("Boustead") is an investment banking firm that executes and advises on IPOs, mergers and acquisitions, capital raises and restructuring assignments in a wide array of industries, geographies and transactions, for a broad client base. Boustead's core value proposition is the ability to create opportunity through innovative solutions and tenacious execution. With experienced professionals in the United States and around the world, Boustead's team moves quickly and provides a broad spectrum of sophisticated financial advice and services. For more information, visit www.boustead1828.com.

About China Renaissance Securities (Hong Kong) Limited

China Renaissance (“CR”) is a leading financial institution that combines private placement advisory, M&A advisory, securities underwriting, research, sales and trading, investment management and other financial services. Providing one-stop financial services across mainland China, Hong Kong and the United States, CR operates a competitive and unique international network that connects China’s capital markets with the rest of the world, serving new economy entrepreneurs and investors globally. CR has offices in Beijing, Shanghai, Hong Kong and New York, with approximately 600 employees. As of March 31, 2018, CR had advised on approximately 700 transactions worth over US$100 billion since the inception, and CR had AUM of approximately US$4.1 billion in new economy investments. For more information, visit www.huaxing.com.

About AMTD Global Markets Limited

AMTD Global Markets Limited (“AMTD”) is a Hong Kong-based comprehensive financial institution dedicated to serving and bridging capital and resources across mainland China, Hong Kong and the globe. As one of the largest Hong Kong-based non-bank financial institution, AMTD has been widely recognized as a pre-eminent capital markets player with leading cross-border investment banking capabilities in Asia. Founded in 2003, AMTD has a long history of promoting technological innovations and the development of New Economy sectors, especially in the fields of FinTech, Artificial Intelligence and Healthcare. For more information, visit www.amtdgroup.com.

Safe Harbor Statement

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Specifically, the Company's statements regarding listing on the NASDAQ Global Market and the completion of the IPO are forward-looking statements. Forward-looking statements are not guarantee of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, risks and uncertainties related to the satisfaction of the customary closing conditions related to the IPO and the listing on NASDAQ. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the U.S. Securities and Exchange Commission, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward‐looking statements to reflect events or circumstances that arise after the date hereof unless required by the applicable laws, regulations or rules.

Contacts
At the Company:
Sabrina Khan, CFO
Aptorum Group Limited
Phone: +852 2117 6611
Email: investor.relations@aptorumgroup.com

06 Dec
2018

知临集团有限公司宣布首次公开发售定价

<BUSINESS WIRE>

知临集团有限公司(以下简称为“知临”或“公司”),作为一家以地处香港、处于临床前阶段的医药研发企业,致力推进一系列崭新医疗及诊断科技的研发和商品化,以应对未被满足的医疗需求。公司于2018年12月3日宣布,公司提交的关于其A类普通股的拟议首次公开发售(“首次公开发售”或“发售”)、每股面值1.00美元(“股份”)、其公开发售定价为每股15.80美元、集资规模至少为1,000万美元、最高为3,000万美元的表格F-1的登记声明已被美国证券交易委员会(“SEC”)宣布有效。公司最多可发售1,898,734股股份以及最多51,990股承销商认股权证。相对而言,某些出售股东最多可发售1,595,235股股份(统称“注册证券”)。公开募股的所得款项不会用于购买出售股东的证券。公司股票预计将于2018年12月18日在纳斯达克全球市场开始交易,股票交易代码为APM。本次发售预计将于2018年12月12日或之前截止,具体截止日期取决于惯例成交条件。

此次发行将以最大努力原则发售。宝德证券有限公司,华兴证券(香港)有限公司,以及尚乘环球市场有限公司将作为发售的联席承销商。

如上所述,公司已向美国证券交易委员会提交了与注册证券(文件号:333-227198)有关的注册声明。此声明已于2018年12月3日宣布生效。此次发售仅通过书面招股说明书进行,该招股说明书为有效注册声明的一部分。您可以通过访问美国证券交易委员会网站www.sec.gov上的EDGAR免费获得招股说明书的副本。或者,您亦可以向宝德证券有限公司索取本次发行有关的招股说明书的副本,电子邮件请致:offerings@boustead1828.com 或致电+1 (949) 502-4409,或邮件请致:Equity Capital Markets, 6 Venture, Suite 265, Irvine, CA 92618, USA.

本新闻稿不构成出售任何公司证券的邀约或建议购买任何公司证券的招揽。本公司证券亦不得在没有注册或注册豁免无法适用的情况下在美国进行邀约或出售。若根据其他州或司法权区的证券法规定,此等要约、招揽或销售在依法登记或满足资格之前属于非法行为,则该等证券亦不得在这些州或司法权区域出售。

关于知临集团有限公司

我们是一家以香港为基地、处于临床前阶段的制药企业。目前正致力推进一系列医疗及诊断科技的研发和商品化,以应对未被满足的医疗需求。我们已获得我们技术的独家许可。此外,我们还在开发某些专有技术作为候选产品。在神经内科,传染病,胃肠科,肿瘤学和其他疾病领域,我们正在寻求治疗和诊断项目(包括寻求使用天然提取物或其衍生物治疗疾病的项目)。我们还有专注于手术机器人的项目。另外,我们于2018年6月创建了一家医疗诊所,名为AML 诊所,其最初针对的是治疗由现代久坐不动的生活方式和人口老龄化引起的慢性病。更多信息,请浏览:www.aptorumgroup.com.

关于宝德证券有限公司

宝德证券有限公司(“宝德”)是一家在各种行业,地域和交易类型上为广泛的客户群执行和建议首次公开招股,并购,资本筹集和重组任务的投资银行。宝德的核心价值主张是通过创新解决方案和强大执行能力来创造机遇。凭借在美国和世界各地经验丰富的专业人士,宝德的团队行动高效并提供广泛的高端金融建议和服务。更多信息,请浏览:www.boustead1828.com.

关于华兴证券(香港)有限公司

华兴证券(香港)有限公司(“华兴证券”)是一家领先的集私募咨询,并购咨询,证券承销,研究,销售和交易,投资管理和其他金融服务于一体的金融机构。华兴证券在中国大陆,香港和美国提供一站式金融服务,通过构建具有竞争性和独特性的国际网络,将中国的资本市场与世界其他地区连接起来,为全球的新经济企业家和投资者提供服务。华兴资本集团在北京、上海、香港和纽约设有办公室,拥有近600位员工。截至2018年3月31日,华兴资本集团已帮助客户成功完成包括首次公开募股、并购和私募融资等超过700宗交易,交易总额逾1,000亿美元,私募股权投资基金资产管理规模近41亿美元。更多信息,请浏览:www.huaxing.com.

关于尚乘环球市场有限公司

尚乘环球市场有限公司(“尚乘”)是一家总部位于香港的综合性金融机构,致力于在中国,香港和全球提供桥接资本和资源。作为香港最大的非银行金融机构之一,尚乘已被公认为卓越的资本市场参与者,在亚洲拥有领先的跨境投资银行业务。尚乘成立于2003年,在促进技术创新和新经济板块发展方面有着悠久的历史,特别是在金融科技,人工智能和医疗保健领域。更多信息,请浏览:www.amtdgroup.com.

安全港声明

本新闻稿包含1995年“私人证券诉讼改革法案”所定义的前瞻性陈述。前瞻性陈述包括有关计划,目的,目标,策略,未来事件或表现的陈述,以及除历史事实陈述之外的基本假设和其他陈述。当公司使用诸如“可能”,“将会”,“打算”,“应该”,“相信”,“期待”,“预期”,“计划”,“估计”或类似的与历史不相关的的表达时,此描述为前瞻性的陈述。具体而言,公司有关在纳斯达克全球市场上市和完成首次公开募股的声明均为前瞻性声明。前瞻性陈述不能保证未来表现,并涉及可能导致实际结果与前瞻性陈述中讨论的公司预期产生重大差异的风险和不确定性。这些陈述受到不确定性和风险的影响,包括但不限于与满足与首次公开招股相关的惯例成交条件和纳斯达克上市相关的风险和不确定性。基于这些原因,谨请投资者不要过分依赖本新闻稿中的任何前瞻性陈述。公司向美国证券交易委员会提交的文件中讨论了其他因素,查阅请致www.sec.gov。除非适用的法律,法规或规则要求,公司没有义务公开修改这些前瞻性陈述以反映在此新闻稿发布日期之后出现的事件或情况。

Contacts
更多信息,请联系公司:
Sabrina Khan 首席财务官
知临集团有限公司
电话: +852 2117 6611
电子邮箱: investor.relations@aptorumgroup.com

https://www.businesswire.com/news/home/20181206006096/zh-CN/

×
×
×
×
使用条款

This Website contains information concerning Aptorum Group Limited (“Aptorum Group”) and its affiliates that may be useful to Aptorum Group’s customers, suppliers, employees, directors and shareholders, as well as members of the general public. However, by using this Website you are accepting all of the terms of this disclaimer notice, including exclusions and limitations of liability. If you do not agree with anything in this notice, you should not use this Website.

Aptorum Group does not claim ownership of the materials and product images on the Website that are provided to us by our third party suppliers.

Where our Website contains links to other sites and resources provided by third parties, these links are provided for your information only. We have no control over the contents of those sites or resources, and accept no responsibility for them or for any loss or damage that may arise from your use of them. These links are provided solely as a convenience to you and not as an endorsement by us of the contents on such third party websites.

While reasonable efforts are made to ensure that the contents of this Website are accurate, this Website and its contents are provided on an “as is,” “as available” basis, without warranties of any kind, including any warranty that the Website will be kept up to date, be true and not misleading, or that the Website will always (or ever) be available for use. Aptorum Group and its affiliates disclaim all warranties, express or implied, with respect to the Website and its contents, including, without limitation, any warranties of accuracy, completeness, timeliness, non-infringement, title, merchantability, or fitness for a particular purpose. Because some jurisdictions do not permit the exclusion of certain warranties, these exclusions may not apply to you.

In no event will Aptorum Group or its affiliates be liable for any incidental, indirect, consequential, or special damages of any kind, or any damages whatsoever, including, without limitation, those resulting from loss of profits, contracts, goodwill, data, information, income, anticipated savings, or business relationships, whether or not Aptorum Group or its affiliates have been advised of the possibility of such damage, arising out of or in connection with the use of this Website or its contents or any other sites linked to this Website.

If you have any concerns about material which appears on our Website, please contact us. We have the right and the ability to remove immediately from our Website any material that is infringing, defamatory, offensive, abusive, harming, deceptive, threatening or otherwise illegal.